NXTC · NextCure, Inc.
$4.24
+0.06 (+1.44%)
At close · Jul 24
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our expectation to incur additional operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that these unaudited financial statements are issued.”View the 10-Q filed May 7, 2026
Market Cap
$15.32M
Shares
3.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.24
Open$4.20
Day$4.02–4.53
52W$1.55–15.74
Avg vol 30d4.2M
Short int1.3M · 36.7% float · 1.0d
Short vol36%
Last earningsMar 4, 2021
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−56%
below
Price vs 50-day avg
−1%
below
RSI (14)
52
neutral
MACD trend
Positive
52-week position
19%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+157%
trailing
6-month return
−61%
trailing
YTD return
−70%
this year
Relative strength
−67%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
1 of 26 funds reported for Jun 30 · net +20 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
36.65% of float · ▲ +734.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — 13F breadth
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+253%
Y/Y
EPS growth
+18%
Y/Y
Free cash flow
$-50.1M
Balance sheet
$22.5M
net cash
Quant / Vol
risk profile
Volatility
236%
annualized · 1-yr
Max drawdown
−89%
past year
ATR
21.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−56%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
19%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
1 of 26 funds reported for Jun 30 · net +20 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
36.65% of float · ▲ +734.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $2
Now $4 · 19%
52-wk high $16
vs 200-day avg -56%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NXTC
this stock
NextCure, Inc.
|
$15.32M | -70.1% | +252.6% | — | 36.7% |
|
ONC
BeOne Medicines Ltd.
|
$472.27B | +7.6% | +22179.2% | 961.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$120.07B | +4.4% | +46.2% | 28.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.35B | -15.4% | +20.8% | 15.9 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NXTC | -29.2% | +157.0% | -60.9% | +165.0% | -70.1% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -27.6% | +156.3% | -67.3% | +166.2% | -78.4% |